A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.

International journal of clinical practice 20121101

Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.

The Prostate 20121001

Re: Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial.

The Journal of urology 20121001

Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia.

Therapeutic advances in urology 20121001

Benign prostatic hyperplasia (BPH) management in the primary care setting.

The Canadian journal of urology 20121001

Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.

BJU international 20120901

Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer.

The Journal of urology 20120901

Expectant management of localized prostate cancer--who, what, when, where and how?

The Journal of urology 20120901

[Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder].

Hinyokika kiyo. Acta urologica Japonica 20120901

Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial.

The Journal of clinical endocrinology and metabolism 20120801

Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1).

Journal of internal medicine 20120701

Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity.

Journal of lipid research 20120701

Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy.

The journal of sexual medicine 20120701

Re: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

The Journal of urology 20120701

A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.

The oncologist 20120701

Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.

World journal of urology 20120601

Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.

Urology 20120601

Words of wisdom: Re: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

European urology 20120601

Promising therapies for treating and/or preventing androgenic alopecia.

Skin therapy letter 20120601

Blood donors on teratogenic drugs and donor deferral periods in a clinical situation.

Vox sanguinis 20120501

Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial.

The Journal of urology 20120501

[Prevention of uro-oncological diseases].

Der Urologe. Ausg. A 20120501

Dutasteride/tamsulosin: in benign prostatic hyperplasia.

Drugs & aging 20120501

[Chemoprevention of prostate cancer - a plea].

Aktuelle Urologie 20120501

High-grade prostatic intraepithelial neoplasia.

Korean journal of urology 20120501

Dutasteride and active surveillance of low-risk prostate cancer.

Lancet (London, England) 20120428

Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.

BJU international 20120401

Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20120401

Combination pharmacological therapies for the management of benign prostatic hyperplasia.

Drugs & aging 20120401

α-blocker monotherapy and α-blocker plus 5-alpha-reductase inhibitor combination treatment in benign prostatic hyperplasia; 10 years' long-term results.

Korean journal of urology 20120401

What (if anything) to do about low-risk prostate cancer.

Lancet (London, England) 20120324

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

Lancet (London, England) 20120324

Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.

JAMA 20120307

The role of 5α-reductase inhibition in men receiving testosterone replacement therapy.

JAMA 20120307

Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial.

BJU international 20120301

Re: Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the reduction by dutasteride of prostate cancer events trial.

European urology 20120301

Dutasteride for the treatment of prostate-related conditions.

Expert opinion on drug safety 20120301

Benign prostatic hyperplasia: from bench to clinic.

Korean journal of urology 20120301

Words of wisdom. Re: Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study.

European urology 20120201

Re: clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.

The Journal of urology 20120201

Re: comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).

The Journal of urology 20120201

Effect of prostatitis on lower urinary tract symptoms: retrospective analysis of prostate biopsy tissue.

Korean journal of urology 20120201

[Pharmacoeconomic evaluation of combination therapy with dutasteride and α1 blocker for treatment of benign prostatic hyperplasia in Japan].

Hinyokika kiyo. Acta urologica Japonica 20120201

Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: a pilot study.

Urologic oncology 20120101

Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage after neoadjuvant cytoreductive therapy.

Brachytherapy 20120101

Testosterone treatment fails to accelerate disease in a transgenic mouse model of spinal and bulbar muscular atrophy.

Disease models & mechanisms 20120101

Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension.

Clinical drug investigation 20120101

Re: Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.

The Journal of urology 20120101

Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type A injection.

BMC urology 20120101

The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases.

Advances in urology 20120101

The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice.

PloS one 20120101

Obesity, body composition, and prostate cancer.

BMC cancer 20120101

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Drug design, development and therapy 20120101

Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice.

PloS one 20120101

Dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic enlargement.

Drugs of today (Barcelona, Spain : 1998) 20120101

Ask the doctor. I take Avodart for my enlarged prostate. But I heard that Avodart increases prostate cancer risk. Is that true? Should I quit taking Avodart?

Harvard health letter 20120101

Prostate cancers detected during 5α-reductase inhibitor use are smaller, de-differentiated, but confined when compared to controls.

Journal of Cancer 20120101

Do no harm: a case in point.

Perspectives in biology and medicine 20120101

Prostatic relaxation induced by loperamide is reduced in spontaneously hypertensive rats.

TheScientificWorldJournal 20120101

Prostate cancer - a biomarker perspective.

Frontiers in endocrinology 20120101

Current status of treatment of spinal and bulbar muscular atrophy.

Neural plasticity 20120101

A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk.

Genetic epidemiology 20120101

Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia.

The Journal of international medical research 20120101

A multiscale, mechanism-driven, dynamic model for the effects of 5α-reductase inhibition on prostate maintenance.

PloS one 20120101

The REDUCE metagram: a comprehensive prediction tool for determining the utility of dutasteride chemoprevention in men at risk for prostate cancer.

Frontiers in oncology 20120101

Improved supersaturation and oral absorption of dutasteride by amorphous solid dispersions.

Chemical & pharmaceutical bulletin 20120101

The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study.

Prostate cancer and prostatic diseases 20111201

Diabetes and prostate cancer risk in the REDUCE trial.

Prostate cancer and prostatic diseases 20111201

What's wrong with chemoprevention of prostate cancer?

The American journal of bioethics : AJOB 20111201

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

PLoS computational biology 20111201

The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function.

The journal of sexual medicine 20111101

A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia.

Asian journal of andrology 20111101

Dutasteride: high-grade prostate cancer. Risky in prostate cancer prevention.

Prescrire international 20111101

PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols.

World journal of urology 20111001

A pilot study of endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging changes with dutasteride in patients with low risk prostate cancer.

BJU international 20111001

Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study.

The Journal of urology 20111001

[Primary prevention of urologic tumors: prostate cancer].

Der Urologe. Ausg. A 20111001

Angioedema associated with dutasteride therapy.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20111001

Macroautophagy is regulated by the UPR-mediator CHOP and accentuates the phenotype of SBMA mice.

PLoS genetics 20111001

Late-onset hypogonadism syndrome and lower urinary tract symptoms.

Korean journal of urology 20111001

Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia.

Korean journal of urology 20111001

[Role of 5 alpha-reductase inhibitors in the chemoprevention of prostate cancer].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20111001

Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110915

National-wide data on the treatment of BPH in Korea.

Prostate cancer and prostatic diseases 20110901

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Urology 20110901

[Prostate cancer].

Der Urologe. Ausg. A 20110901

[Prostate cancer. Current and practice-relevant news from urology in 2011].

Der Urologe. Ausg. A 20110901

Montelukast for symptom control of interstitial cystitis.

The Annals of pharmacotherapy 20110901

Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial.

Applied health economics and health policy 20110901

Editorial comment.

Urology 20110901

Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results.

Korean journal of urology 20110901

Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia.

International neurourology journal 20110901

Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).

BJU international 20110801

Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.

Urology 20110801

The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

The New England journal of medicine 20110714

Ethanol enhances neurosteroidogenesis in hippocampal pyramidal neurons by paradoxical NMDA receptor activation.

The Journal of neuroscience : the official journal of the Society for Neuroscience 20110706

Low serum testosterone levels are poor predictors of sexual dysfunction.

BJU international 20110701

Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory?

Journal of general internal medicine 20110701

Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.

The Journal of urology 20110701

Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia.

Korean journal of urology 20110701

Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin.

Patient related outcome measures 20110701

Development and characterization of dutasteride bearing liposomal systems for topical use.

Current drug discovery technologies 20110601

Chemoprevention of prostate cancer.

Acta oncologica (Stockholm, Sweden) 20110601

Current status of transurethral prostatectomy: a korean multicenter study.

Korean journal of urology 20110601

Targeting 5α-reductase for prostate cancer prevention and treatment.

Nature reviews. Urology 20110531

Gas chromatography/mass spectrometry based hair steroid profiling may reveal pathogenesis in hair follicles of the scalp.

Rapid communications in mass spectrometry : RCM 20110515

Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.

The Journal of steroid biochemistry and molecular biology 20110501

The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study.

BJU international 20110501

[Non dietetic environmental risk factors in prostate cancer].

Actas urologicas espanolas 20110501

Biopsy misidentification identified by DNA profiling in a large multicenter trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110501

The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the combination of avodart and tamsulosin (CombAT) study.

BJU international 20110501

Association of IL10, IL10RA, and IL10RB polymorphisms with benign prostate hyperplasia in Korean population.

Journal of Korean medical science 20110501

Inhibition of the M. tuberculosis 3β-hydroxysteroid dehydrogenase by azasteroids.

Bioorganic & medicinal chemistry letters 20110415

Association of polymorphisms in CYP19A1 and CYP3A4 genes with lower urinary tract symptoms, prostate volume, uroflow and PSA in a population-based sample.

World journal of urology 20110401

Re: Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the combination of avodart and tamsulosin trial.

The Journal of urology 20110401

Re: The Effects of Combination Therapy With Dutasteride and Tamsulosin on Clinical Outcomes in Men With Symptomatic Benign Prostatic Hyperplasia: 4-Year Results From the CombAT Study.

The Journal of urology 20110401

Designing smarter cancer prevention trials.

Nature 20110324

Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study.

Japanese journal of clinical oncology 20110301

Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.

The journal of sexual medicine 20110301

Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.

BJU international 20110301

Castration-resistant prostate cancer: targeted therapies and individualized treatment.

The oncologist 20110301

Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.

European urology 20110201

Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.

European urology 20110201

Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen.

Cancer prevention research (Philadelphia, Pa.) 20110201

Oral testosterone with and without concomitant inhibition of 5α-reductase by dutasteride in hypogonadal men for 28 days.

The Journal of urology 20110201

The effects of 5α-reductase inhibition on benign prostatic hyperplasia treated by photoselective vaporization prostatectomy with the 120 Watt GreenLight HPS laser system.

Journal of the American College of Surgeons 20110201

Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial.

The Lancet. Neurology 20110201

Dutasteride for spinal and bulbar muscular atrophy.

The Lancet. Neurology 20110201

Annual drug update: 2010 in review.

The Nurse practitioner 20110201

[Cost-effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain].

Actas urologicas espanolas 20110201

[Comment to: «Cost-Effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain»].

Actas urologicas espanolas 20110201

Dutasteride: novel milestones in prostate cancer chemoprevention.

Drugs of today (Barcelona, Spain : 1998) 20110201

Benign prostatic hyperplasia: An overview of existing treatment.

Indian journal of pharmacology 20110201

Re: Fritz H. Schröder, Monique J. Roobol. The REDUCE Trial. Eur Urol 2010;58:253-255.

European urology 20110101

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.

The Journal of urology 20110101

Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer.

Cancer causes & control : CCC 20110101

Prostate cancer: Dutasteride improves accuracy of diagnosis but may not prevent cancer development.

Nature reviews. Urology 20110101

Specific pharmacokinetic aspects of the urinary tract.

Handbook of experimental pharmacology 20110101

[Dutasteride in the treatment of benign prostatic hyperplasia: an update].

Zhonghua nan ke xue = National journal of andrology 20110101

Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders.

Current pharmaceutical design 20110101

Methods to predict and lower the risk of prostate cancer.

TheScientificWorldJournal 20110101

Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.

Journal of hematology & oncology 20110101

How to reduce your cancer risk: mechanisms and myths.

International journal of general medicine 20110101

Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population.

PloS one 20110101

Chemoprevention of prostate cancer with nutrients and supplements.

Cancer management and research 20110101

Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.

Therapeutics and clinical risk management 20110101

Alopecia: evaluation and treatment.

Clinical, cosmetic and investigational dermatology 20110101

Identification of novel functional inhibitors of acid sphingomyelinase.

PloS one 20110101

5-α reductase inhibitors and prostate cancer prevention: where do we turn now?

BMC medicine 20110101

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.

Molecular cancer 20110101

Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability.

Patient preference and adherence 20110101

Suppressive effects of the antiandrogen agent, chlormadinone acetate and the 5alpha-reductase inhibitor, dutasteride on prostate weight and intraprostatic androgen levels in rats.

Arzneimittel-Forschung 20110101

Finasteride and male fertility.

Journal of human reproductive sciences 20110101

[Combined dutasteride and tamsulosin].

Urologia 20110101

An update on the changing indications for androgen deprivation therapy for prostate cancer.

Prostate cancer 20110101

Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence.

Journal of carcinogenesis 20110101

Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.

PloS one 20110101

Lifetime economic burden of prostate cancer.

BMC health services research 20110101

How to appraise the effectiveness of treatment.

Indian journal of urology : IJU : journal of the Urological Society of India 20110101

Understanding results: P-values, confidence intervals, and number need to treat.

Indian journal of urology : IJU : journal of the Urological Society of India 20110101

Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.

Drug, healthcare and patient safety 20110101

Hormones and prostate carcinogenesis: Androgens and estrogens.

Journal of carcinogenesis 20110101

Oncogenic activation of ERG: A predominant mechanism in prostate cancer.

Journal of carcinogenesis 20110101

What's new in androgenetic alopecia: approvals, long-term safety data, cancer risk and treatment options for women.

Journal of drugs in dermatology : JDD 20110101

Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA.

ISRN dermatology 20110101

Beyond the HPA Axis: Progesterone-Derived Neuroactive Steroids in Human Stress and Emotion.

Frontiers in endocrinology 20110101

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy.

Korean journal of urology 20101201

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml.

Korean journal of urology 20101201

Analysis of initial baseline clinical parameters and treatment strategy associated with medication failure in the treatment of benign prostatic hyperplasia in Korea.

International neurourology journal 20101201

[The effects of dutasteride on voiding and storage symptoms in men with benign prostatic hyperplasia].

Hinyokika kiyo. Acta urologica Japonica 20101201

The effect of short-term dutasteride intake in early-stage prostate cancer: analysis of 148 patients who underwent three-dimensional prostate mapping biopsy.

Urology 20101101

PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.

The Journal of urology 20101101

5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review.

BJU international 20101101

Comparative effect of finasteride and dutasteride on chromogranin A levels.

Anticancer research 20101101

[Effect of one month treatment with dutasteride on transurethral resection of the prostate].

Actas urologicas espanolas 20101101

Operating characteristics of a partial-block randomized crossover bioequivalence study for dutasteride, a drug with a long half-life: investigation through simulation and comparison with final results.

Journal of clinical pharmacology 20101001

Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.

The Prostate 20101001

The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects.

The Journal of steroid biochemistry and molecular biology 20101001

Words of wisdom. Re: effect of dutasteride on the risk of prostate cancer.

European urology 20101001

Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Expert opinion on pharmacotherapy 20101001

Prostate cancer: A closer look at the initial results from the REDUCE trial.

Nature reviews. Urology 20101001

Active surveillance for favorable-risk prostate cancer: a short review.

Korean journal of urology 20101001

The different reduction rate of prostate-specific antigen in dutasteride and finasteride.

Korean journal of urology 20101001

Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.

Endocrine-related cancer 20100901

Dutasteride and prostate cancer risk.

Current urology reports 20100901

Evolving role of 5-alpha reductase inhibitors in chemoprevention.

Nature reviews. Clinical oncology 20100901

Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole GL, Bostwick DG, Brawley OW, et al.

European urology 20100901

Prevention strategies in prostate cancer.

Current oncology (Toronto, Ont.) 20100901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100901

Dutasteride and prostate cancer.

The New England journal of medicine 20100819

Dutasteride and prostate cancer.

The New England journal of medicine 20100819

Dutasteride and prostate cancer.

The New England journal of medicine 20100819

Dutasteride and prostate cancer.

The New England journal of medicine 20100819

The REDUCE Trial.

European urology 20100801

Dutasteride reduces incident prostate cancer in men after negative prostate biopsy.

Evidence-based medicine 20100801

Can chemoprevention reduce the risk of prostate cancer?

Clinical chemistry 20100801

Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study.

Journal of the American Academy of Dermatology 20100801

Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research.

Cancer prevention research (Philadelphia, Pa.) 20100801

Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole GL, Bostwick DG, Brawley OW, et al. REDUCE Study Group. N Engl J Med 2010;362:1192-202.

European urology 20100801

Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole G, Bostwick D, Brawley O, et al. N Engl J Med 2010;362:1192-202.

European urology 20100801

Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.

The Journal of urology 20100701

Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.

International journal of clinical practice 20100701

The use of 5-alpha reductase inhibitors for the prevention of prostate cancer.

Cancer biology & therapy 20100701

Enzyme-linked immunosorbent assays for doping control of 5alpha-reductase inhibitors finasteride and dutasteride.

Analytica chimica acta 20100625

New tests for prostate cancer may be nearing the clinic.

Journal of the National Cancer Institute 20100602

Prostate needle biopsy quality in reduction by dutasteride of prostate cancer events study: worldwide comparison of improvement with investigator training and centralized laboratory processing.

Urology 20100601

Secretagogue type, sex-steroid milieu, and abdominal visceral adiposity individually determine secretagogue-stimulated cortisol secretion.

European journal of endocrinology 20100601

Male androgenetic alopecia.

Expert opinion on pharmacotherapy 20100601

Editorial comment.

Urology 20100601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100601

Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.

BJU international 20100501

Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams.

Urology 20100501

Update on chemoprevention for prostate cancer.

Current opinion in urology 20100501

Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.

The Journal of urology 20100501

A practical guide to male hypogonadism in the primary care setting.

International journal of clinical practice 20100501

Dutasteride (Avodart) for prevention of prostate cancer.

The Medical letter on drugs and therapeutics 20100419

Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia.

BJU international 20100401

Effect of dutasteride on the risk of prostate cancer.

The New England journal of medicine 20100401

Chemoprevention of prostate cancer.

The New England journal of medicine 20100401

The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment.

Korean journal of urology 20100401

[Treatment of benign prostate hyperplasia].

Orvosi hetilap 20100321

Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial.

Urology 20100301

Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities.

The Journal of steroid biochemistry and molecular biology 20100215

Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention.

Cancer research 20100215

An overview on 5alpha-reductase inhibitors.

Steroids 20100201

Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.

World journal of urology 20100201

Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism.

Cancer biology & therapy 20100201

Chemoprevention of prostate cancer.

The Urologic clinics of North America 20100201

The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.

European urology 20100101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100101

RP-HPLC Method for the Estimation of Dutasteride in Tablet Dosage Form.

Indian journal of pharmaceutical sciences 20100101

Management of the adult with congenital adrenal hyperplasia.

International journal of pediatric endocrinology 20100101

Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises.

International journal of pediatric endocrinology 20100101

Cancer biomarker discovery: the entropic hallmark.

PloS one 20100101

Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells.

International journal of clinical and experimental medicine 20100101

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

BMJ (Clinical research ed.) 20100101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100101

Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies.

Health and quality of life outcomes 20100101

Glutathione S-transferase (GST) gene variants and risk of benign prostatic hyperplasia: a report in a North Indian population.

Asian Pacific journal of cancer prevention : APJCP 20100101

Transdermal delivery of bioidentical progesterone using dutasteride (A 5α-reductase inhibitor): a pilot study.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20100101

Evaluation of plasma enzyme activities using gas chromatography-mass spectrometry based steroid signatures.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091215

Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone.

Endocrine-related cancer 20091201

Awareness of prostate cancer among patients and the general public: results of an international survey.

Prostate cancer and prostatic diseases 20091201

Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts.

The Prostate 20091201

Clinical features of spinal and bulbar muscular atrophy.

Brain : a journal of neurology 20091201

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20091115

Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.

The Prostate 20091101

Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.

BJU international 20091101

Contemporary hair transplantation.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20091101

The effect of dutasteride on the efficacy of photoselective vaporization of the prostate: results of a randomized, placebo-controlled, double-blind study (DOP trial).

Urology 20091101

Prostate cancer prevention (AUGUST 2009).

Cleveland Clinic journal of medicine 20091101

Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.

The Canadian journal of urology 20091001

Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.

Clinical genitourinary cancer 20091001

On call. My brother needed surgery for an enlarged prostate at age 60. I am a few months shy of my 50th birthday, and my urine stream is starting to slow down a bit. Is there anything I can do to avoid following in my brother's footsteps?

Harvard men's health watch 20091001

Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia.

International journal of urology : official journal of the Japanese Urological Association 20090901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090901

High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series.

British journal of cancer 20090707

Treatment of postmenopausal frontal fibrosing alopecia with oral dutasteride.

Journal of the American Academy of Dermatology 20090701

Is it worth the wait?

BJU international 20090701

A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.

The Prostate 20090601

Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study.

Urology 20090601

Androgens and hair loss.

Current opinion in endocrinology, diabetes, and obesity 20090601

Molecular profiles of finasteride effects on prostate carcinogenesis.

Cancer prevention research (Philadelphia, Pa.) 20090601

The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?

Canadian Urological Association journal = Journal de l'Association des urologues du Canada 20090601

Finasteride to prevent prostate cancer: a new chapter.

Harvard men's health watch 20090601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090601

Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.

European urology 20090501

Pharmacological approaches to reducing the risk of prostate cancer.

European urology 20090501

The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.

Current opinion in urology 20090501

Overview of pivotal studies for prostate cancer risk reduction, past and present.

Urology 20090501

Frontal fibrosing alopecia: treatment with oral dutasteride and topical pimecrolimus.

Journal of the European Academy of Dermatology and Venereology : JEADV 20090501

Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study.

Urology 20090401

Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.

BJU international 20090401

Prostate cancer: a serious disease suitable for prevention.

BJU international 20090401

[Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: a randomized, double-blind, placebo-controlled, parallel-group, dose response study].

Hinyokika kiyo. Acta urologica Japonica 20090401

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090401

Biodegradable braided poly(lactic-co-glycolic acid) urethral stent combined with dutasteride in the treatment of acute urinary retention due to benign prostatic enlargement: a pilot study.

BJU international 20090301

Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men.

The Journal of clinical endocrinology and metabolism 20090301

Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.

BJU international 20090301

Hair loss in women.

Seminars in cutaneous medicine and surgery 20090301

Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20090301

The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.

European urology 20090201

Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy.

The Journal of urology 20090201

Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer.

The journal of sexual medicine 20090201

Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH.

Prostate cancer and prostatic diseases 20090101

5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.

Prostate cancer and prostatic diseases 20090101

Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy.

Scandinavian journal of urology and nephrology 20090101

The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms.

Health and quality of life outcomes 20090101

Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate.

Clinical interventions in aging 20090101

Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.

Therapeutics and clinical risk management 20090101

Drugs associated with more suicidal ideations are also associated with more suicide attempts.

PloS one 20090101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090101

The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.

Prostate cancer and prostatic diseases 20090101

Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate.

Scandinavian journal of urology and nephrology 20090101

Therapeutic options in the treatment of benign prostatic hyperplasia.

Patient preference and adherence 20090101

A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia.

Indian journal of urology : IJU : journal of the Urological Society of India 20090101

Effect of dutasteride on the expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in rat and human prostate tissue.

Scandinavian journal of urology and nephrology 20090101

Finasteride-its impact on sexual function and prostate cancer.

Journal of cutaneous and aesthetic surgery 20090101

Finasteride induced Gynecomastia: Case report and Review of the Literature.

International journal of trichology 20090101

Update on the management of prostate cancer with goserelin acetate: patient perspectives.

Cancer management and research 20090101

The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial.

European urology 20081201

Antipsychotic-like properties of 5-alpha-reductase inhibitors.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20081201

The role of combination medical therapy in benign prostatic hyperplasia.

International journal of impotence research 20081201

5-alpha reductase inhibitors and erectile dysfunction: the connection.

The journal of sexual medicine 20081201

Androgen deficiency and defective intracrine processing of dehydroepiandrosterone in salivary glands in Sjögren's syndrome.

The Journal of rheumatology 20081101

Association between 5-alpha reductase inhibition and risk of hip fracture.

JAMA 20081008

Dutasteride (Avodart) with tamsulosin (Flomax) for benign prostatic hyperplasia.

The Medical letter on drugs and therapeutics 20081006

Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals.

The journal of sexual medicine 20081001

Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.

Diabetes 20081001

Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.

Urology 20081001

Medical treatments for male and female pattern hair loss.

Journal of the American Academy of Dermatology 20081001

Sex hormone influence on hepatitis in young male A/JCr mice infected with Helicobacter hepaticus.

Infection and immunity 20080901

In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors.

The Journal of steroid biochemistry and molecular biology 20080901

Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily.

Clinical interventions in aging 20080901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20080901

Preventing prostate cancer: new analyses put finasteride back on the map.

Journal of the National Cancer Institute 20080820

Benign prostatic hyperplasia and lower urinary tract symptoms in African Americans and Latinos: treatment in the context of common comorbidities.

The American journal of medicine 20080801

Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.

International journal of clinical practice 20080701

Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.

The Journal of urology 20080701

The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.

Expert review of anticancer therapy 20080701

By the way, doctor. I have been taking Avodart for my BPH, along with Flomax, but finasteride may be less expensive. Should I switch?

Harvard health letter 20080701

The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men.

The Journal of urology 20080601

Androgens and prevention of prostate cancer.

Current opinion in endocrinology, diabetes, and obesity 20080601

A connection between the mitochondrial permeability transition pore, autophagy, and cerebral amyloidogenesis.

Journal of proteome research 20080601

[Dutasteride in the treatment of hormone refractory prostate cancer].

Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20080601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20080601

5-Alpha reductase inhibitors in men with an enlarged prostate: an evaluation of outcomes and therapeutic alternatives.

The American journal of managed care 20080501

Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.

The American journal of managed care 20080501

Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men.

The American journal of managed care 20080501

Cost comparison of finasteride and dutasteride for enlarged prostate in a managed care setting among Medicare-aged men.

The American journal of managed care 20080501

The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.

The Journal of urology 20080401

Current status of 5alpha-reductase inhibitors in the treatment of benign hyperplasia of prostate.

Indian journal of medical sciences 20080401

5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.

Best practice & research. Clinical endocrinology & metabolism 20080401

A review of hormonal therapy for female pattern (androgenic) alopecia.

Dermatology online journal 20080315

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20080301

Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.

European urology 20080201

The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.

The Journal of urology 20080201

Dutasteride prior to contrast-enhanced colour Doppler ultrasound prostate biopsy increases prostate cancer detection.

European urology 20080101

Dutasteride significantly improves quality of life measures in patients with enlarged prostate.

Prostate cancer and prostatic diseases 20080101

Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey.

International journal of clinical practice 20080101

Pharmacokinetics and pharmacodynamics of oral testosterone enanthate plus dutasteride for 4 weeks in normal men: implications for male hormonal contraception.

Journal of andrology 20080101

Nanomilled oral testosterone plus dutasteride effectively normalizes serum testosterone in normal men with induced hypogonadism.

Journal of andrology 20080101

Novel concepts in androgen receptor blockade.

Cancer journal (Sudbury, Mass.) 20080101

Dutasteride: a review of its use in the management of prostate disorders.

Drugs 20080101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20080101

Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease.

BMC neurology 20080101

[The experience in dutasteride use before transurethral prostatic resection for large adenoma].

Urologiia (Moscow, Russia : 1999) 20080101

Strategies for prostate cancer prevention: Review of the literature.

Indian journal of urology : IJU : journal of the Urological Society of India 20080101

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.

Contemporary clinical trials 20071101

Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.

Contemporary clinical trials 20071101

Post-coital gross hematuria: an unusual presentation of benign prostatic hyperplasia.

Asian journal of andrology 20071101

Decreased efficiency of potassium-titanyl-phosphate laser photoselective vaporization prostatectomy with long-term 5 alpha-reductase inhibition therapy: is it true?

Urology 20071101

[Gynecomastia and dutasteride].

Medicina clinica 20071027

Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines.

Investigational new drugs 20071001

Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer.

The Journal of urology 20071001

Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.

Andrologia 20071001

Impurity profile study of dutasteride.

Die Pharmazie 20071001

Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial.

The Journal of urology 20070901

Chemoprevention of prostate cancer: agents and study designs.

The Journal of urology 20070901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20070901

[Benign prostatic hyperplasia: medical therapy].

MMW Fortschritte der Medizin 20070816

5alpha-reductase inhibition for men with enlarged prostate.

Journal of the American Academy of Nurse Practitioners 20070801

Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride.

The Prostate 20070701

Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.

The Journal of urology 20070601

Female pattern hair loss: current treatment concepts.

Clinical interventions in aging 20070601

The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men.

The Journal of clinical endocrinology and metabolism 20070501

Re: The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.

The Journal of urology 20070501

Benign prostatic hyperplasia: when to 'watch and wait,' when and how to treat.

Cleveland Clinic journal of medicine 20070501

The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.

The Journal of urology 20070401

A review of phase III clinical trials of prostate cancer chemoprevention.

Annals of the Royal College of Surgeons of England 20070401

Dutasteride improves male pattern hair loss in a randomized study in identical twins.

Journal of cosmetic dermatology 20070301

Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride.

BJU international 20070301

A review of combination therapy in patients with benign prostatic hyperplasia.

Clinical therapeutics 20070301

Update on the use of dutasteride in the management of benign prostatic hypertrophy.

Clinical interventions in aging 20070301

Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH).

Therapeutics and clinical risk management 20070301

[Dutasteride-induced gynecomastia].

Medicina clinica 20070224

Medical therapy for benign prostatic hyperplasia--present and future impact.

The American journal of managed care 20070201

A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.

The American journal of managed care 20070201

Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs.

The American journal of managed care 20070201

Finasteride versus dutasteride: a real-world economic evaluation.

The American journal of managed care 20070201

Medical treatment of benign prostatic hyperplasia.

Postgraduate medical journal 20070201

Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma.

Histology and histopathology 20070101

The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.

Prostate cancer and prostatic diseases 20070101

Prevention of prostate cancer: more questions than data.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20070101

Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.

Archives of andrology 20070101

A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.

Clinical therapeutics 20070101

Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway.

Scandinavian journal of urology and nephrology 20070101

Method for evaluating prediction models that apply the results of randomized trials to individual patients.

Trials 20070101

Identification of the patient with enlarged prostate: diagnosis and guidelines for management.

Osteopathic medicine and primary care 20070101

Randomised controlled trials for evaluating the prescribing impact of information meetings led by pharmacists and of new information formats, in General Practice in Italy.

BMC health services research 20070101

[Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?].

Urologiia (Moscow, Russia : 1999) 20070101

Pathogenesis of prostate cancer and hormone refractory prostate cancer.